From the Research
The maximum daily dose of Diamicron MR (modified-release gliclazide) is 120 mg, as supported by the most recent and highest quality study 1. Treatment typically starts with a lower dose of 30-60 mg once daily with breakfast, which can be gradually increased based on blood glucose response. Dose adjustments should be made in increments of 30 mg, with at least one month between adjustments to properly assess the glycemic effect. Diamicron MR is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells, making it effective for type 2 diabetes management. The modified-release formulation allows for once-daily dosing, improving adherence and providing more consistent blood glucose control throughout the day. Some key points to consider when using Diamicron MR include:
- Starting with a lower dose and gradually increasing as needed
- Taking the medication at the same time each day, preferably with breakfast
- Being aware of potential side effects, including hypoglycemia, especially when starting treatment or increasing the dose
- Regular blood glucose monitoring to ensure optimal dosing and minimize hypoglycemic risk According to the study published in 2022 1, gliclazide in the modified release formulation provides good 24-h glycemic efficacy comparable to most other groups of glucose-lowering drugs, with fewer hypoglycemic events and less weight gain compared to other sulfonylureas. Additionally, a 2018 study 2 highlights the differences between currently available sulfonylureas, with gliclazide modified release possessing many desirable properties, including high glucose-lowering efficacy, once-daily oral administration, and cardiovascular safety. Overall, Diamicron MR is a effective and safe treatment option for type 2 diabetes, with a maximum daily dose of 120 mg, as supported by the most recent and highest quality evidence 1.